SCYX
SCYNEXIS
No price yet
Announcements
Nothing here yet
Daily updates
- SCYNEXIS completed a 25-subject Phase 1 study of oral SCY-770 in healthy volunteers, reporting favorable safety and tolerability across higher dose levels.Oct 6, 2026
- SCY-770 is being evaluated in a Phase 1 trial in autosomal dominant polycystic kidney disease, with topline data expected in Q3 2026.Sep 19, 2026
FDA designations
Nothing here yet
News
- SCYNEXIS reports Phase 1 results for SCY-770, an oral selective AMPK activator being developed for autosomal dominant polycystic kidney diseaseOct 6, 2026
- SCYNEXIS reported dosing the first participants in a Phase 1 SAD/MAD trial of intravenous SCY-247Feb 26, 2026
- SCYNEXIS received FDA QIDP and Fast Track designations for SCY-247Jan 21, 2026
- SCYNEXIS announces positive results from Phase 1 single ascending dose and multiple ascending dose study of its second-generation Fungerp (SCY-247)Sep 30, 2025
- SCYNEXIS resumes patient dosing in Phase 3 MARIO studyMay 28, 2025